

Why FebriDx?

Because frontline healthcare teams need answers fast.



Fast and easy results after 10 minutes using a fingerstick



Rule out bacterial infection with 99% NPV¹



Supports confident decision-making at the point of care



Instrument-free and fully portable



Intended for patients aged 12–64 with symptoms less than 7 days and within 3 days of fever onset




Designed for Urgent Care, Primary Care and Pharmacy Clinic settings

Let's elevate point-of-care diagnostics together.

FebriDx is changing how frontline providers approach acute respiratory infection care across point-of-care settings.

As healthcare regulations and guidelines continue to evolve, now is an ideal time to explore how rapid point-of-care diagnostics can empower your team to deliver faster, more informed decisions. This can help improve patient outcomes, reduce unnecessary antibiotic use, and support broader antimicrobial stewardship goals.



PHASESCIENTIFIC

Partner with us

-  phasescientificamericas.com
-  657-233-5880
-  USsales@phasesci.com
-  10527 Garden Grove Blvd
Garden Grove, California 92843

Distributed in partnership with Lumos Diagnostics

STAY IN TOUCH



FebriDx

Bacterial or not?



Get clear answers
after 10 minutes

PHASESCIENTIFIC



Stop guessing. Start guarding.

Every year in the U.S., millions of antibiotic prescriptions are written for acute respiratory infections that aren't bacterial¹. This contributes to the rise of antimicrobial resistance (AMR), a growing public health crisis.


FebriDx empowers frontline healthcare teams to play a critical role in antimicrobial stewardship.

By identifying whether an infection is likely bacterial or non-bacterial after 10 minutes, FebriDx helps support appropriate antibiotic use and informed clinical decision-making.

- Ensure that bacterial infections are not overlooked
- Helps combat antibiotic overuse and resistance
- Strengthens pharmacy-based test-to-treat programs
- Deployable in CLIA-waived healthcare settings without instrumentation

Let's raise the bar for point-of-care clarity and protect antibiotic effectiveness for future generations.

Differentiate bacterial from non-bacterial acute respiratory infections at the point of care



Ideal for point-of-care test-to-treat models.

Cold and flu-like symptoms + Fever, sore throat or cough + Nasal congestion + Shortness of breath

1

Collect a fingerstick blood sample (lancet included in device)




2

Transfer the blood to the test strip via capillary action




3

Push the buffer release button down completely until it clicks



4

Read results after 10 minutes



Refer to the complete IFU on our FebriDx webpage.
phasescientificamericas.com/products-and-services/indicaid-poc/indicaid-febri-dx-test

FebriDx® is FDA 510(k)-cleared for prescription use only. It is intended for use in patients aged 12 to 64 presenting with signs and symptoms of acute respiratory infection, who have had symptoms for less than 7 days and within three days of fever onset. FebriDx results are to be used in conjunction with other clinical and diagnostic findings and are not intended as a stand-alone diagnostic tool. This test does not identify specific pathogens or determine infection severity. FebriDx is intended for use by healthcare professionals in CLIA-waived settings.

References

1. Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic accuracy of a bacterial and viral biomarker point-of-care test in the outpatient setting. JAMA Netw Open, 2022, 5(10): e2234588.
2. U.S. Food and Drug Administration. 510(k) summary for FebriDx Bacterial/Non-Bacterial Point-of-Care Assay. K260787.